Premium
A Protein Biosynthesis Machinery Strategy for Identifying P53 PTC ‐Rescuing Compounds as Synergic Anti‐Tumor Drugs
Author(s) -
Zhou Jingjing,
Qiu Chengbin,
Pi Ni,
Li Sicong,
Cheng Xiyao,
Zhang Lei,
Chen Yao,
Huang Yongqi,
Sun Yuhui,
Su Zhengding
Publication year - 2018
Publication title -
chemistryselect
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 34
ISSN - 2365-6549
DOI - 10.1002/slct.201802635
Subject(s) - fusion protein , cancer research , doxorubicin , green fluorescent protein , biosynthesis , protein biosynthesis , chemistry , cancer cell , biology , cancer , gene , biochemistry , chemotherapy , genetics , recombinant dna
The readthrough of premature termination codons (PTCs) is a promising strategy for curing PTC‐causing diseases. In cancers, the p53 anti‐tumor activity is often disabled by forming premature terminated p53 protein (p53 PTC ). Currently, there are lack of p53 PTC ‐rescuing drugs. Herein we designed a feasible strategy for identifying p53 PTC ‐rescuing compounds using protein biosynthesis machinery in E. coli cells and the lung cancer H1299 cells both harboring p53 PTC ‐GFP fusion protein expression cassettes. Rescued p53 PTC protein enabled a GFP‐tag for fluorescence spectroscopic measurements. Our data revealed that the aminoglycoside G418 not only efficiently rescued p53 PTC in H1299 cells, but also synergistically enhanced the efficacy of antitumor drug doxorubicin. Our work gave an insight into the discovery of p53 PTC ‐rescuing drugs for cancer therapy.